February 9, 2021 -- Taysha Gene Therapies has established multiyear collaborations with the Cleveland Clinic and the University of Texas Southwestern (UTSW) Gene Therapy Program to advance next-generation minigene payloads for adeno-associated virus (AAV) gene therapies.
The new gene therapies will be used for the treatment of genetic epilepsies and additional central nervous system disorders. Taysha will have an exclusive option on the new payloads, constructs, and intellectual property associated with, and arising from, the research conducted under the agreement.
Researchers at the Cleveland Clinic Lerner Research Institute will create minigene payloads designed to address the limitations of vector packaging capacity in AAV gene therapy. UTSW will create and evaluate vector constructs for in vivo and in vitro efficacy.
Copyright © 2021 scienceboard.net